J&J Medical Connect
TECVAYLI®

(teclistamab-cqyv)

+ Save link
J&J Medical Connect

Connect with us

Connect with us

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TECVAYLI® (teclistamab-cqyv)

Medical Information

TECVAYLI – Pre-treatment and Management of Cytokine Release Syndrome (CRS)

Last Updated: 11/21/2025

SUMMARY

  • Johnson & Johnson does not recommend any practices, procedures, or usage that deviate from the product labeling or are not approved by the regulatory agencies.
  • Please refer to local labeling for recommended pre-treatment medications to reduce the risk of CRS and CRS management recommendations.
  • Consider further management per current practice guidelines or institutional guidelines.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 13 November 2025.